Result
€337,721 ▲ 483%
The result rose in 2025 from €57,893 to €337,721.
QUALIFY Life Sciences
Lifetime
2 annual accounts with figures on one time axispeak €1.5m (2025)
€1.5m▲ 633%
peak €337,721 (2025)
€337,721▲ 483%
peak €404,613 (2025)
€404,613▲ 505%
€891,017▲ 218%
Board5 names since 2024
4 directorsDB BRAND SRL and 3 others
Documentsfilings and deeds
30-07-20261 day before the deadline
2025micro format
Gross margin from €203,288 to €1.5mResult from €57,893 to €337,721Resignation: Maud Lombard (director) 03-10Appointment: Maud Lombard (director) 02-04Equity from €66,893 to €404,613Debts from €280,558 to €891,017
Key points
from the 2025 annual accountsDebts
€891,017 ▲ 218%
Debts rose by €610,459 in 2025.
Investments
€146,582 7.3 × depreciation
Green is investment, beige is depreciation.
Staff
16 employees on 31-12-2025
In 2025, 24 people joined and 14 left.
At the same address
280 companies
Position in the sector
€337,721
Higher net result than 95% of companies in head offices and management consultancy. Sector median €27,132 · 39,384 companies.
Checked score
95
Excellent
Financially stronger than 63% of micro companies in head offices and management consultancy (NACE 70)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%
The dashed line is the sector median: 0.1% across 48,570 companies (NACE 70, micro).
Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).
Last 24 months
02-2025: 0.4%
03-2025: 0.4%● unchanged vs 02-2025
04-2025: 0.4%● unchanged vs 03-2025
05-2025: 0.4%● unchanged vs 04-2025
06-2025: 0.4%● unchanged vs 05-2025
07-2025: 0.5%▲ +0.1 percentage points vs 06-2025
08-2025: 0.5%● unchanged vs 07-2025highest value
09-2025: 0.1%▼ -0.4 percentage points vs 08-2025
10-2025: 0.1%● unchanged vs 09-2025
11-2025: 0.1%● unchanged vs 10-2025
12-2025: 0.1%● unchanged vs 11-2025
01-2026: 0.1%● unchanged vs 12-2025
02-2026: 0.1%● unchanged vs 01-2026
03-2026: 0.1%● unchanged vs 02-2026
04-2026: 0.1%● unchanged vs 03-2026
05-2026: 0.1%● unchanged vs 04-2026
06-2026: 0.1%● unchanged vs 05-2026
07-2026: 0.1%● unchanged vs 06-2026
08-2026: < 0.1%▼ -0.1 percentage points vs 07-2026
09-2026: < 0.1%● unchanged vs 08-2026lowest value
10-2026: < 0.1%● unchanged vs 09-2026lowest value
11-2026: < 0.1%● unchanged vs 10-2026lowest value
Financial strengthStrong
Score breakdown
lowers risk
Sector: Activities of head offices; management consultancy activities (NACE 70)
Size: total assets €1.3m
Liquidity: current ratio 1.40, cash €363,181
Figures for financial year 2025 (filed on 01-08-2026)
Calculation
The band follows from the bankruptcy probability. 10 more points roughly halve it.
| 75-100 | Excellent | under 0.55% |
| 60-74 | Healthy | 0.55% to 1.5% |
| 45-59 | Fair | 1.5% to 4.2% |
| 25-44 | Weak | 4.2% to 15.0% |
| 0-24 | Critical | over 15.0% |
Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro). It does better than 31% of them on solvency, 38% on liquidity, 84% on profitability and 99% on growth.
The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.
The probability rests on the annual accounts with balance sheet date 31-12-2025.
Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.
Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).
Comparable companies, two years later
In July 2024, 3,127 companies had the same profile as QUALIFY Life Sciences has now. Each dot stands for 8 companies, two years later.
97.2%
were still trading
1.9%
stopped another way
0.8%
went bankrupt
That fits the bankruptcy probability of QUALIFY Life Sciences itself: < 0.1% within 12 months.
Test of the method
The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.
| Group | Expected | Actual |
|---|---|---|
| 1 | 0.2% | 0.2% |
| 2 | 0.3% | 0.5% |
| 3 | 0.5% | 0.6% |
| 4 | 0.7% | 0.8% |
| 5 | 0.9% | 0.9% |
| 6 | 1.3% | 1.5% |
| 7 | 1.6% | 1.8% |
| 8 | 1.8% | 1.8% |
| 9 | 3.0% | 3.1% |
| 10 | 5.6% | 6.2% |
A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.
This is an observation about 3,127 companies, not a prediction for QUALIFY Life Sciences. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.
Credit verdict
Credit of up to €35,000 on 30-day terms, only on tighter conditions: young company (under 3 years) without a track record
Liquidity is tight, with a current ratio of 1.4 (1.91 in 2024), below the usual 1.5. Short-term debt is 64.4% and cash 28% of total assets. 68.8% of the assets are financed with debt and provisions.
Credit check for an amount and term of your choice
Show the recommended maximum and see how the verdict changes with amount, term and advance.
The scores and ratios are Checked's own calculations, not a credit decision.
Signals
Six signals.
lowers riskraises riskneutral
raises risk · Young company
Founded in 2024, 2 years ago. Young companies fail more often than established ones; the risk is highest 2 to 8 years after founding.
KBO · incorporation dateAge against the risk zone
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 30-07-2026, 1 day ahead of the deadline.
NBB · 2 filingsDeviation from the deadline
2025
1 day early
2024
25 days late
← before the deadline
after the deadline →
tick = median of all Belgian filingsring = median in the sector
The company filed its last 2 accounts on average 12 days after the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.
Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
Companies Code · seven monthsWhere today falls in the filing period
10-11-2026 today31-12-2026 year end31-07-2027 deadline
Board and ownership
DB
DB BRAND SRL
Director, Dorian De Brabandère, since 10-01-2024
SS
So'Z SRL
Director, Zerroune Sophian
- DE BRABANDERE Dorian Tanguy Ariane Olivier Marie 9,000 sharesdeed of 12-01-2024
Recent changes
2 directors appointed, 1 resignation
Resignation: Dorian De Brabandère · Appointments: DB BRAND SRL and So'Z SRL · Permanent representatives: Dorian De Brabandère and Zerroune Sophian · General meeting of 16-04-2026 · Gazette deed
Resignation: Maud Lombard (director)
Appointment: MAUD&US SRL (director) · General meeting of 23-09-2025 · Gazette deed
Registered in the Peppol Directory
Reachable for e-invoices through 0208:1004523684
Appointment: Maud Lombard (director)
General meeting of 06-03-2025 · Gazette deed
Comparable companies
same main activity, similar in size and age| Company | ||||
|---|---|---|---|---|
| QUALIFY Life Sciences Brussels | €1.3m | €1.5m | 31.2% | - |
| Down2Earth Partners II Antwerp | €1.3m | €1.5m | 82.3% | 2 |
| AGC Conseil Ixelles | €1.5m | €1.3m | 81.4% | - |
| JR Conseil Uccle | €1.7m | €1.2m | 66.1% | - |
| G. FEDERICO ECONOMICS Uccle | €1.8m | €1.1m | 77.1% | - |
| PIVANTO Leuven | €1.7m | €1.5m | 74.4% | - |
| SAMAFLOW Puurs-Sint-Amands | €1.7m | €1.2m | 67.6% | - |
These companies have the same main activity as QUALIFY Life Sciences: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €1.3m and €1.8m, founded between 2023 and 2024.
Official details
Source: KBO- Status
- Active since 10-01-2024Normal situation
- Registered office
- 281 active companies are registered at this address12 started in the 12 months before. Source: KBO register, as of 10 November 2026.
- Activity
- Business and other management consultancyNACE 70200
- Establishment unit
- 2.355.345.3871050 Brussels, since 10-01-2024
- Financial year end
- 31 December
- Peppol
- Reachable since 30-07-2025
Annual accounts 2025
- ≈ €2.7mestimated
- €1.3m▲ 273%
- Employeeson 31-12-2025
- 16▲ 167%
- Filing
- Filed on 30-07-2026, 1 day before the end of the filing period
Insights on QUALIFY Life Sciences
QUALIFY Life Sciences has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €404,613 and a net result of €337,721.
Its solvency ranks better than 31% of 39,368 sector peers (NACE 70, financial year 2025). The computed 12-month bankruptcy probability is below 0.1% (very low).
Sources: KBO register, filings at the National Bank, Belgian Official Gazette. Click a figure with a dotted line for the item and the filing.
Key facts about QUALIFY Life Sciences
- What is the company number of QUALIFY Life Sciences?
- The company number of QUALIFY Life Sciences is 1004.523.684. The VAT number is the same number with BE in front: BE 1004.523.684.
- Where is QUALIFY Life Sciences based?
- The registered office is at Louizalaan 251, 1050 Brussels.Company details
- What does QUALIFY Life Sciences do?
- According to the KBO register, the main activity is business and other management consultancy (NACE 70200).
- What is the legal form of QUALIFY Life Sciences?
- QUALIFY Life Sciences is a private limited company (BV).
- When was QUALIFY Life Sciences founded?
- QUALIFY Life Sciences was founded on 10-01-2024.
- Is QUALIFY Life Sciences still active?
- Yes, QUALIFY Life Sciences is an active enterprise in the KBO register.
- How many employees does QUALIFY Life Sciences have?
- QUALIFY Life Sciences had an average of 13.6 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
- What is the turnover of QUALIFY Life Sciences?
- The turnover in financial year 2025 is ≈ €2.7m. This figure is estimated from the gross margin of €1.5m and 38 comparable companies (NACE 70200). It probably lies between €1.8m and €3.5m.
- Is QUALIFY Life Sciences profitable?
- In financial year 2025, QUALIFY Life Sciences made a profit of €337,721.
- Where can I find the annual accounts of QUALIFY Life Sciences?
- QUALIFY Life Sciences filed 2 annual accounts with the National Bank of Belgium, the latest for financial year 2025.
- When are the next annual accounts of QUALIFY Life Sciences due?
- QUALIFY Life Sciences must file the annual accounts for financial year 2026 by 31-07-2027.Timeline
Next steps
Work out how much credit to give this customer and on what payment terms.Credit check Check what to know before you do business with this company.Supplier due diligence Check whether you can accept this company as a client under the anti-money-laundering law.AML client file Check which of your other customers you can e-invoice via Peppol.Peppol check Compare this company with its sector.Sector benchmark See what changed in the latest annual accounts.What changed
See how customers, suppliers and banks see your own company and what to improve first.